Headlines
Private equity GTCR strikes $4.8 billion deal to buy Zentiva, FT reports
Published by Global Banking & Finance Review®
Posted on September 11, 2025
1 min readLast updated: January 22, 2026
Global Banking & Finance Review®
Company
Published by Global Banking & Finance Review®
Posted on September 11, 2025
1 min readLast updated: January 22, 2026
GTCR has agreed to a $4.8 billion deal to buy Zentiva from Advent International, enhancing its presence in the generic drug market.
(Reuters) - Private equity firm GTCR has struck a 4.1 billion euro ($4.8 billion) deal to buy Czech generic drugmaker Zentiva from Advent International, the Financial Times reported on Wednesday, citing unidentified sources.
Reuters could not immediately confirm the report. GTCR, Advent and Zentiva did not immediately respond to a Reuters request for comment.
The deal has been finalized and is expected to be announced within days, the newspaper said.
Boston-based Advent bought Zentiva, which makes a wide range of generic and over-the-counter drugs, from French pharmaceutical giant Sanofi for 1.9 billion euros in 2018.
Zentiva operates in over 30 countries and employs more than 5,000 people, according to the company's website.
India's Economic Times newspaper reported last month that Aurobindo Pharma was leading the race to buy Zentiva for up to $5.5 billion.
($1 = 0.8548 euros)
(Reporting by Gnaneshwar Rajan in Bengaluru; Editing by Sonia Cheema and Mrigank Dhaniwala)
GTCR has agreed to a deal worth 4.1 billion euros, which is approximately $4.8 billion.
GTCR acquired Zentiva from Advent International.
Zentiva produces a wide range of generic and over-the-counter drugs.
Advent International bought Zentiva in 2018 for 1.9 billion euros.
Zentiva operates in over 30 countries and employs more than 5,000 people.
Explore more articles in the Headlines category
